Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes

Aims We aimed to identify a novel biomarker involved in the early events leading to an acute coronary syndrome (ACS) and evaluate its role in diagnosis and risk stratification. Methods and results Biomarker identification was based on gene expression profiling. In coronary thrombi of ACS patients, cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) gene transcripts were highly up-regulated compared with peripheral mononuclear cells. In a murine ischaemia-reperfusion model (I/R), myocardial Cyr61 expression was markedly increased compared with the controls. Cyr61 levels were determined in human serum using an enzyme-linked immunosorbent assay. Cohorts of ACS (n = 2168) referred for coronary angiography, stable coronary artery disease (CAD) (n = 53), and hypertrophic obstructive cardiomyopathy (HOCM) patients (n = 15) served to identify and evaluate the diagnostic and prognostic performance of the biomarker. Cyr61 was markedly elevated in ST-elevation myocardial infarction patients compared with non-ST-elevation myocardial infarction/unstable angina or stable CAD patients, irrespective of whether coronary thrombi were present. Cyr61 was rapidly released after occlusion of a septal branch in HOCM patients undergoing transcoronary ablation of septal hypertrophy. Cyr61 improved risk stratification for all-cause mortality when added to the reference GRACE risk score at 30 days (C-statistic 0.88 to 0.89, P = 0.001) and 1 year (C-statistic 0.77 to 0.80, P < 0.001) comparable to high-sensitivity troponin T (30 days: 0.88 to 0.89, P < 0.001; 1 year: 0.77 to 0.79, P < 0.001). Similar results were obtained for the composite endpoint of all-cause mortality or myocardial infarction. Conversely, in a population-based case-control cohort (n = 362), Cyr61 was not associated with adverse outcome. Conclusion Cyr61 is a novel early biomarker reflecting myocardial injury that improves risk stratification in ACS patients.

[1]  A. von Eckardstein,et al.  Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score , 2018, European heart journal. Acute cardiovascular care.

[2]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[3]  A. von Eckardstein,et al.  Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort , 2018, European heart journal. Acute cardiovascular care.

[4]  L. Räber,et al.  Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes , 2016, Circulation.

[5]  J. Greenslade,et al.  Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. , 2016, JAMA cardiology.

[6]  S. Engelhardt,et al.  Essential Role for Premature Senescence of Myofibroblasts in Myocardial Fibrosis. , 2016, Journal of the American College of Cardiology.

[7]  B. Lindahl,et al.  A 1-h Combination Algorithm Allows Fast Rule-Out and Rule-In of Major Adverse Cardiac Events. , 2016, Journal of the American College of Cardiology.

[8]  S. Blankenberg,et al.  Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome. , 2016, The American journal of medicine.

[9]  L. Räber,et al.  Prognostic value of PCSK9 levels in patients with acute coronary syndromes. , 2016, European heart journal.

[10]  A. Akhmedov,et al.  Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Ki-Hyun Kim,et al.  The Matricellular Protein CCN1 Mediates Neutrophil Efferocytosis in Cutaneous Wound Healing , 2015, Nature Communications.

[12]  L. Räber,et al.  Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland , 2015, Heart.

[13]  F. le Noble,et al.  MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2 , 2014, Nature Communications.

[14]  C. Schindler,et al.  One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. , 2012, Archives of internal medicine.

[15]  Akiko Maehara,et al.  Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. , 2012, Journal of the American College of Cardiology.

[16]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[17]  Lester F. Lau,et al.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets , 2011, Nature Reviews Drug Discovery.

[18]  M. Hsiao,et al.  Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: a therapeutic benefit for arthritis. , 2011, Arthritis and rheumatism.

[19]  U. Eriksson,et al.  Matricellular Signaling Molecule CCN1 Attenuates Experimental Autoimmune Myocarditis by Acting as a Novel Immune Cell Migration Modulator , 2010, Circulation.

[20]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[21]  S. Lye,et al.  Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human trophoblast. , 2010, Endocrinology.

[22]  L. Lau,et al.  The Matricellular Protein CCN1/CYR61 Induces Fibroblast Senescence and Restricts Fibrosis in Cutaneous Wound Healing , 2010, Nature Cell Biology.

[23]  L. Lau,et al.  Matricellular Protein CCN1 Activates a Proinflammatory Genetic Program in Murine Macrophages , 2010, The Journal of Immunology.

[24]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[25]  Tobias Reichlin,et al.  Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.

[26]  Stefan Blankenberg,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction. , 2009, The New England journal of medicine.

[27]  Ronit Meyuhas,et al.  A Key Role for Cyclic AMP-Responsive Element Binding Protein in Hypoxia-Mediated Activation of the Angiogenesis Factor CCN1 (CYR61) in Tumor Cells , 2008, Molecular Cancer Research.

[28]  Vincent Mooser,et al.  The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome , 2008, BMC cardiovascular disorders.

[29]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[30]  Mia M. Thi,et al.  Fluid Shear Stress Upregulates Vascular Endothelial Growth Factor Gene Expression in Osteoblasts , 2007, Annals of the New York Academy of Sciences.

[31]  M. Ballmaier,et al.  The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. , 2007, Blood.

[32]  D. Morrow,et al.  Benchmarks for the Assessment of Novel Cardiovascular Biomarkers , 2007, Circulation.

[33]  Ju-Young Kim,et al.  Forkhead Transcription Factor FOXO3a Is a Negative Regulator of Angiogenic Immediate Early Gene CYR61, Leading to Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia , 2007, Circulation research.

[34]  L. Lau,et al.  The Matricellular Protein CCN1 Is Essential for Cardiac Development , 2006, Circulation research.

[35]  M. Takigawa,et al.  Comparable response of ccn1 with ccn2 genes upon arthritis: An in vitro evaluation with a human chondrocytic cell line stimulated by a set of cytokines , 2005, Cell Communication and Signaling.

[36]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, JAMA.

[37]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .

[38]  H. Drexler,et al.  Regulation of Proangiogenic Factor CCN1 in Cardiac Muscle: Impact of Ischemia, Pressure Overload, and Neurohumoral Activation , 2004, Circulation.

[39]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[40]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[41]  K. Nakao,et al.  Angiogenic protein Cyr61 is expressed by podocytes in anti-Thy-1 glomerulonephritis. , 2003, Journal of the American Society of Nephrology : JASN.

[42]  Simon C Watkins,et al.  CYR61 (CCN1) Is Essential for Placental Development and Vascular Integrity , 2002, Molecular and Cellular Biology.

[43]  L. Lau,et al.  Pro-angiogenic Activities of CYR61 (CCN1) Mediated through Integrins αvβ3 and α6β1 in Human Umbilical Vein Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[44]  A. Lichtenberg,et al.  Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II , 2002, Circulation.

[45]  L. Lau,et al.  Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. , 2002, Blood.

[46]  L. Lau,et al.  Activation-dependent Adhesion of Human Platelets to Cyr61 and Fisp12/Mouse Connective Tissue Growth Factor Is Mediated through Integrin αIIbβ3 * , 1999, The Journal of Biological Chemistry.

[47]  T. V. Kolesnikova,et al.  CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Baris Gencer,et al.  2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. , 2015, Revista espanola de cardiologia.

[49]  松前 宏信.  CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model , 2008 .

[50]  L. Lau,et al.  Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. , 2002, The Journal of biological chemistry.

[51]  L. Lau,et al.  Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3). , 1999, The Journal of biological chemistry.